1. Hemoadsorption improves kidney microcirculatory oxygenation and oxygen consumption, ameliorates tubular injury, and improves kidney function in a rat model of sepsis-induced AKI.
- Author
-
Ergin B, Kutucu DE, Kapucu A, van Dam W, Moretto L, Heyman P, and Ince C
- Subjects
- Animals, Rats, Male, Kidney pathology, Kidney metabolism, Kidney Tubules pathology, Kidney Tubules metabolism, Oxygen metabolism, Creatinine blood, Acute Kidney Injury etiology, Acute Kidney Injury therapy, Acute Kidney Injury metabolism, Sepsis complications, Sepsis therapy, Microcirculation, Disease Models, Animal, Oxygen Consumption
- Abstract
Microcirculatory dysfunction, hypoxia, and inflammation are considered to be central in the pathogenesis of sepsis-induced acute kidney injury (AKI). In this experimental study, we hypothesized that extracorporeal removal of inflammatory cytokines by hemoadsorption (HA) therapy may mitigate renal injury associated with sepsis-induced AKI. To this end, we investigated renal microcirculatory oxygenation and perfusion, oxygen consumption, lactate, systemic hemodynamic variables, tubular cell integrity, inflammatory mediators, and kidney function in a rat model of septic AKI elicited by endotoxin infusion. Three groups of rats were investigated on extracorporeal circulation: HA only, LPS, and LPS + HA. Endotoxin infusion reduced cortex microcirculatory oxygenation and raised creatinine and lactate levels. Renal microcirculatory oxygenation, measured by two independent techniques (phosphorescence (µPO
2 ) and spectrophotometry/Doppler (µHbO2sat and [Formula: see text])), was ameliorated by HA therapy. The renal oxygen consumption, lactate and creatinine levels were restored in the LPS + HA group. A reduced amount of injured tubular cells was found in histological analysis of the kidneys. This experimental study demonstrated an improvement in multiple determinants of kidney oxygenation, damage, and systemic blood perfusion by HA in a clinically relevant rat model of septic AKI. Further studies are needed to optimize and support the clinical use of HA as a renal protective strategy., Competing Interests: Declarations Competing interests Dr. Ince is the CSO of Active Medical BV, Leiden, The Netherlands, a company that provides devices (OxyCam), software (MicroTools), education (Microcirculation Academy), and services related to clinical microcirculation. All other authors declare that they have no conflict of interest., (© 2024. The Author(s).)- Published
- 2024
- Full Text
- View/download PDF